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Introduction
Aging, rheumatic heart diseases, and the growing prevalence of 
heart and vascular system conditions increased the incidence of 
 severe valvular dysfunctions (e.g., stenosis and insufficiency) that 
require surgically implanted valve replacements. With over 300,000 
valves implanted worldwide yearly, the global prosthetic heart 
valve market comprising mechanical and bioprosthetic replace-
ments [1] is expanding [2]. Due to their durability, the mechanical 
valves are the gold standard treatment for patients up to 60 years, 
even though the life-long anticoagulant treatment required to pre-
vent thrombosis [3] reduces the patient’s quality of life [4]. Bio-
prosthetic valves based on glutaraldehyde-fixed xenogeneic (e.g. 
bovine pericardium or porcine valves) or allogeneic (e.g. from 
human donor) materials that preserve the native-like geometry and 
structure mitigate the need for anticoagulants by ensuring a more 
physiological hemodynamic profile. 
The standard surgical procedure to replace the valve is highly 
invasive and uses a cardiopulmonary bypass machine to provide 
the extracorporeal circulation and ventilation for the patient. De-
spite the good perioperative and long-term results, this procedure 
cannot be performed on patients with more comorbidities [5]. In 
addition, prosthesis-associated complications (e.g., thromboembo-
lism, infection, bioprosthetic valve degeneration and calcification, 
mechanical valve failure) have still considerable impact on patient’s 
life [6]. 
A possible alternative for young patients, but suitable only for 
small valvular defects (e.g., small perforations or isolated spots of 
endocarditis), is represented by the reconstructive procedures (i.e., 
valve repair). The aim of valve repair is to replace the damaged area 
of the leaflet with a patch of autologous, or xenogeneic and glutar-
aldehyde-fixed, pericardium [7]. This technique has the great ad-
vantage of eliminating the complications associated with the valve 
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Summary
The incidence of severe valvular dysfunctions (e.g., ste-
nosis and insufficiency) is increasing, leading to over 
300,000 valves implanted worldwide yearly. Clinically 
used heart valve replacements lack the capacity to grow, 
inherently requiring repetitive and high-risk surgical in-
terventions during childhood. The aim of this review is 
to present how different tissue engineering strategies 
can overcome these limitations, providing innovative 
valve replacements that proved to be able to integrate 
and remodel in pre-clinical experiments and to have 
promising results in clinical studies. Upon description of 
the different types of heart valve tissue engineering (e.g., 
in vitro, in situ, in vivo, and the pre-seeding approach) 
we focus on the clinical translation of this technology. In 
particular, we will deepen the many technical, clinical, 
and regulatory aspects that need to be solved to endure 
the clinical adaptation and the commercialization of 
these promising regenerative valves. 
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replacement [6]. However, it is primarily used for mitral valve dis-
ease because of the enhanced complexity of performing the recon-
structive surgery in the aortic environment.
To overcome the limited applicability of the valve repair and to 
extend the surgical valve replacement to the increasing number of 
patients with higher perioperative risk profile, surgeons introduced 
the use of catheters to implant minimally invasively the valves [8]. 
To be successful, this method requires the combination of a crim-
pable stent and a valve that can be folded into a delivery device 
without breaking. Considering these requirements, currently the 
only valves available for this approach are the bioprosthetic ones. 
Interestingly, the minimally invasive procedure is now considered 
as the treatment of choice for those frail elderly patients previously 
considered as inoperable because of comorbidities. The possibility 
of extending this technique also to a younger patient cohort is ap-
pealing but limited by the use of glutaraldehyde-fixed bioprosthe-
ses that, especially in children, undergo degenerative failure [9]. 
Additionally, both mechanical and bioprosthetic valves lack the 
capacity to remodel and grow with the patient, inherently leading 
to multiple surgeries to replace the valve, especially in pediatric pa-
tients, with an increasing risk of morbidity and mortality. This 
strengthens the need for regenerative heart valve replacements 
suitable for pediatric patients and for the minimally invasive im-
plantation technique.
The aim of this review is to present how tissue engineering 
strategies can overcome these limitations, providing innovative 
valve replacements with regenerative and growth capacity (see 
‘Tissue Engineering Approaches for Heart Valve Replacements’ 
below). The clinical translation of these tissue engineering ap-
proaches has been reviewed in ‘Clinical Translation of Tissue-En-
gineered Valve Replacements’ (see below), focusing not only on the 
clinical trials but also on the still open technical, clinical, and regu-
latory challenges that need to be solved to endure the clinical adap-
tation of these regenerative valves. Finally, a critical conclusion will 
summarize how these regenerative replacements will offer a life-
long solution for the increasing numbers of cardiovascular patients 
worldwide.
Tissue Engineering Approaches for Heart Valve  
Replacements
Tissue engineering has been proposed as a possible approach to 
fulfill the need for valve replacements able to remodel, regenerate, 
and grow with the patient [10]. 
The original in vitro heart valve tissue engineering paradigm, as 
defined in 1993 by Langer and Vacanti [11], comprises a 3D scaf-
fold seeded with autologous cells and subsequent in vitro tissue 
formation in a bioreactor. Once the new extracellular matrix 
(ECM) is formed, the living construct can be implanted enabling 
further in vivo tissue growth and remodeling.
Since then, significant progress has been made in the develop-
ment and application of bioresorbable materials for the develop-
ment of a tissue-engineered heart valve (TEHV). In general, the 
scaffold should be biocompatible, favor cell adhesion, and have 
sufficient porosity, permeability and thrombus resistance. In addi-
tion, material degradation should be carefully balanced with matrix 
formation in order to always retain sufficient mechanical proper-
ties to sustain the cyclic loading of the heart. 
Nowadays, several materials that can fulfill these specific re-
quirements have been investigated as scaffold for TEHVs. Alloge-
neic and xenogeneic heart valves provide the ideal geometry for a 
starter scaffold; however, they required glutaraldehyde-fixation to 
prevent the immunological response that limits cell infiltration and 
remodeling potential of the replacement [12]. Decellularization of 
these valves favors the long-term graft durability and preserves the 
biomechanical properties, without impeding cell infiltration [13]. 
Natural-based polymers such as gelatin, collagen, and fibrin are 
fast degrading non-toxic materials with low mechanical properties 
and a non-immunogenic response. On the other hand, biodegrad-
able synthetic polymers such as poly-glycolic acid (PGA) and poly-
lactic acid (PLA) have tunable mechanical properties that can be 
suitable for the development of strong and durable valve replace-
ments with thin and flexible leaflets. Moreover, the material can be 
tuned to ensure sufficient mechanical properties at the time of im-
plantation and controlled scaffold degradation while endogenous 
tissue is formed over time. The large variety of possible materials 
and scaffold fabrication methods suitable for the development of 
polymeric valve replacements have been reviewed elsewhere 
[14–16].
By using different combinations of cells and scaffold material, 
researchers have developed TEHVs following the classic in vitro 
tissue engineering approach (see ‘Technical Challenges: Cell and 
Scaffold Optimization’ below). More recently, cell-free constructs 
aimed at exploiting the regenerative capability of the body to re-
populate the scaffold have been introduced in a technique defined 
in situ tissue engineering (see ‘Clinical Challenges: Beating the 
Gold Standard Valve Replacements’ below). Other methodologies, 
such as the pre-seeding and the in vivo approach, are reviewed in 
‘Regulatory Challenges: Towards Commercialization’ (see below).
In vitro TEHVs
To create in vitro TEHVs, researchers combine different bio-
compatible scaffolds with autologous cells capable of producing a 
collagen-rich ECM. A variety of cell types have been described for 
this scope. The most popular autologous cell sources used are the 
vascular-derived myofibroblasts and endothelial cells harvested 
from the recipient saphenous [17] or forearm [18] vein. Alterna-
tively, cells derived from bone marrow, adipose tissue, and periph-
eral blood have also the potential to generate heart valves in vitro 
[19–23]. In contrast to vascular cells, these cell sources can be ob-
tained without surgical intervention, thereby enabling potential 
adaption into in a routine clinical scenario.
Similarly, a multitude of scaffold materials, ranging from poly-
meric substrates to decellularized tissues, have been used for the 
pre-clinical evaluation of in vitro produced TEHVs (table 1). De-
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cellularized xenografts cultured in vitro with myofibroblast and 
endothelial cells showed enhanced in vivo functionality and en-
dothelialization in a sheep model [24]. Compared to xenogeneic 
tissues, allogeneic valves favor proliferation, differentiation, and 
survival of the seeded cells [25], but the availability of valve allo-
grafts is limited by donor shortage. Therefore, easily available bio-
degradable synthetic and natural polymers have been extensively 
applied and proved to be suitable for the fabrication of in vitro 
TEHVs based on autologous cells and bioreactor systems to en-
hance cell proliferation and tissue formation. Promising results 
were reported by several groups for both in vitro [19, 26–28] and in 
vivo models [22, 29–36] (table 1). In 1995, Shinoka and colleagues 
Table 1. Overview of some pre-clinical evaluations of TEHVs in large animal models 
Scaffold material Cells Implantation Main results Year
In-vitro TEHV
PGA autologous 
ECs and MyoFBs 
surgical replacement of one pulmonary 
leaflet of lambs
11 weeks follow-up
ECM remodeling, no stenosis nor regurgitation
the cells were retained upon implantation 
1995–1996
[24, 37]
PGA + P4HB autologous 
ECs and MyoFBs
surgical replacement of the pulmonary 
valve of lambs
20 weeks follow-up
increased ECM and endothelialization over time
no stenosis, native-like mechanical properties 
2000
[29]
Fibrin autologous ECs 
and MyoFBs
surgical replacement of the pulmonary 
valve of adult sheep
12 weeks follow-up
tissue remodeling and endothelialization
contraction of the leaflet
insufficiency over time
2009
[32]
PGA + PLA autologous 
ECs and MyoFBs
surgical replacement of the pulmonary 
valve of lambs
20 weeks follow-up
good early remodeling 
leaflet functionality reduced with time
increased regurgitation over time
2010
[31]
PGA + P4HB autologous 
ECs and MyoFBs
transcathether replacement of the  
pulmonary valve of adult sheep
8 weeks follow-up 
mobile but thickened leaflets
endothelialization and remodeling
2010
[33]
Pre-seeded TEHV
Decellularized ovine 
pulmonary valve
autologous ECs surgical replacement of the pulmonary 
valve of sheep
improved endothelialization 2006
[82]
PGA + P4HB autologous 
BMC pre-seeding
transcathether replacement of the 
 pulmonary valve of Chacma baboons
4 weeks follow-up
successful implantation
good leaflet function
host cell repopulation and endothelialization
2011
[83]
In-situ cell-free TEHV
Decellularized ovine 
aortic valve
– surgical replacement of the aortic valve 
of adult sheep
9 months follow-up 
sufficient functionality
no degeneration
minor calcifications
2009
[84]
PGA + P4HB MyoFBs, then  
decellularized
transcathether replacement of the 
 pulmonary valve of Chacma baboons
8 weeks follow-up
mobile and thin leaflets
recellularization and
endothelialization
2013
[45]
PGA + P4HB MyoFBs, then  
decellularized
transcathether replacement of the 
 pulmonary valve of adult sheep
24 weeks follow-up
ECM remodeling and host cell repopulation 
compromised coaptation at late time points
2014
[44]
Decellularized  
porcine aortic  
valve
– surgical replacement of the aortic valve 
of adult pigs
15 months follow-up
adequate functionality
cell repopulation and remodeling
vasa vasorum
2014
[85]
Fibrin dermal FBs, then 
decellularized
surgical replacement of the aortic valve 
of adult sheep
24 weeks follow-up
ECM remodeling and host cell repopulation;
no calcification
good functionality
2015
[36]
ECs = Endothelial cells; ECM = extracellular matrix; FBs = fibroblasts; MyoFbs = myofibroblasts; PGA = poly-glycolic acid; P4HB = poly-4-hydroxybutyrate;  
PLA = poly-lactic acid.
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[37] were the first to successfully implant in lamb a tissue-engi-
neered leaflet based on the biodegradable polymer PGA and on au-
tologous vascular-derived cells. In a similar approach, Hoerstrup et 
al. [29] showed physiological-like mechanical behavior and signs of 
remodeling and endothelialization of a TEHV implanted in the 
pulmonary position in lambs. More recently, the possibility to 
merge the TEHVs with the innovative, minimally invasive tran-
scathether technique was proven feasible in sheep [33]. 
Despite encouraging early results, thickening of the leaflets has 
been observed in several studies in which in vitro cultured autolo-
gous cells were used [31, 33]. The thickening, due to excessive 
ECM formation [38], is most likely an effect of the immune re-
sponse towards the in vitro expanded cells present in the valves 
[39] and results in leaflet retraction and consequent valve insuffi-
ciency [33]. 
In situ TEHVs
The in situ tissue engineering approach relies on the regenera-
tive capacity of the body to remodel and form new tissue by re-
cruiting endogenous (circulating) cells while the scaffold degrades 
over time after providing the initial mechanical functionality [15, 
16]. When compared to the classical in vitro method, this tech-
nique represents a straightforward alternative to produce off-the-
shelf available implants that are designed to guide and control cell 
recruitment and remodeling towards a native-like functional living 
tissue [16]. The cell-free scaffold is particularly important for this 
approach, as it should possess sufficient mechanical properties im-
mediately upon implantation and favor endogenous cell adhesion 
and growth. Being allogeneic tissues hardly available, decellular-
ized xenogeneic materials have gained large interest for this appli-
cation [13], showing promising functionality and re-cellularization 
upon implantation in sheep [40], pigs [41], and dogs [42] (table 1). 
Nevertheless, the risk for disease transmission and immune reac-
tion to the use of xenogeneic materials have motivated researchers 
to develop new strategies to achieve engineered off-the-shelf avail-
able allogeneic valve replacements. 
By decellularization of TEHVs obtained via the classic in vitro 
approach, we have obtained non-immunogenic valve substitutes 
with intact mechanical and biological properties [43]. This ap-
proach solved the thickening and retraction of the leaflets that was 
previously reported for living TEHVs [33], by introducing also the 
off-the-shelf availability of the product. In addition, it can be effi-
ciently combined with the transcathether approach, without limit-
ing valve functionality and remodeling potential, as demonstrated 
in sheep [44] and baboons [45]. With a similar approach, others 
investigated the use of fibrin-based decellularized TEHVs, show-
ing good in vitro [46] and in vivo functionality, with almost com-
plete cell repopulation in the systemic circulation of sheep [36]. 
Despite the promising pre-clinical results of these decellularized 
valves, the time and cost associated with scaffold production 
pushed the researchers to develop new alternatives. Cell-free, 
readily available valves can be produced by using biodegradable 
and biocompatible polymeric materials; upon implantation, the 
polymer will provide a suitable environment for endogenous cell 
adhesion, and support ECM formation and remodeling towards a 
completely autologous tissue replacement when the starting mate-
rial is fully degraded [47]. 
Other Tissue Engineering Approaches
Another method to reduce the time and costs associated with 
the in vitro production of TEHVs is the pre-seeding of the scaffold 
with autologous cells. Although the most appropriate cell type for 
in vitro pre-seeding is not established yet, bone marrow-derived 
mesenchymal stem cells (MSCs) proved to be an attractive cell 
source. In fact, they were successfully used to re-seed decellularized 
matrices [25] and synthetic scaffolds [19, 35], showing differentia-
tion into a phenotype similar to valvular interstitial cells [48]. 
These cells also demonstrated anti-thrombogenic potential [49] 
and immunosuppressive properties [50], the ability to stimulate in 
vivo endothelialization [51], and differentiation potential into en-
dothelial cells, (myo)fibroblasts, and smooth muscle cells [25]. Im-
portantly, MSCs are easy to access, facilitating their translation into 
clinical practice [52]. Importantly, they may induce the homing 
and differentiation of autologous host cells through a paracrine se-
cretion of growth and chemotactic factors [53]. 
Another line of research, defined as in vivo tissue engineering, 
focus on exploiting the foreign body reaction upon subcutaneous 
implantation (e.g., in the peritoneal cavity) of a non-degradable 
mold. The formed fibrotic collagen-rich matrix encapsulating the 
foreign material [54] follows the shape of the mold, creating a 
TEHV [55]. The construct can be harvested and transplanted as a 
non-immunogenic, non-toxic, autologous replacement that may 
possess growth and regenerative capacity. A similar prototype has 
been tested under pulmonary conditions in vitro [55] and im-
planted using minimally invasive transcathether techniques as aor-
tic replacements in a recent study in goats [56]. Despite the early 
positive results, the remodeling of the collagenous matrix is ques-
tionable in humans: the thickness of the fibrotic capsule formed 
around the mold is uncontrollable, and the method is highly inva-
sive, requiring long in vivo pre-transplantation time to obtain me-
chanically robust grafts [57], making it an unsuitable techniques 
for emergency cases.
Clinical Translation of Tissue-Engineered Valve  
Replacements
Novel engineered valves with repair and growth capacity have 
the potential to provide a permanent solution for pediatric and 
young adult patients. However, the clinical adaptation of regenera-
tive valve replacements depends on their superiority compared to 
today’s bioprostheses in terms of functionality and durability. Clin-
ical trials have already been performed to investigate the function-
ality and remodeling potential of in vitro TEHVs based on decel-
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
2 
- 1
1/
10
/2
01
6 
1:
14
:3
6 
PM
Dijkman/Fioretta/Frese/Pasqualini/HoerstrupTransfus Med Hemother 2016;43:282–290286
lularized allografts [58–60] and xenografts [18], seeded and cul-
tured with endothelial cells prior to implantation (table 2). By tar-
geting the capability of the body to self-regenerate, cell-free 
decellularized matrixes have also been tested in clinics as scaffold 
materials for the in situ approach (table 3). 
Despite the enormous progress in the development of TEHVs 
that show regenerative potential in the pre-clinical studies (table 1) 
and the clinical trials exploring the potentiality of the tissue engi-
neering approaches (tables 2, 3), a clinically relevant product is not 
yet realized, and many technical, regulatory, and clinical challenges 
still need to be solved.
Technical Challenges: Cell and Scaffold Optimization
To prevent in vivo deterioration, TEHVs should be able to re-
generate similarly to the native valve, where valvular interstitial 
cells synthesize and remodel the ECM ensuring growth and repair 
[61]. 
Seeding and culturing endothelial and endothelial progenitor 
cells proved to be a valuable method to reduce scaffold thrombo-
genicity and inflammatory response (table  2). In vitro cultured 
TEHVs based on decellularized human pulmonary valves seeded 
with endothelial cells have demonstrated excellent hemodynamic 
performance and good functionality in clinical trials up to 10 years 
[59]. Thanks to the good functionality and the lack of degenera-
tion, calcification and immunoreactivity, the use of decellularized 
allografts for both pulmonary and aortic valves is promising, with 
minimal occurrence of re-operations and possibility for adaptive 
growth [62, 63]. Unfortunately, the availability of allografts is lim-
ited by donor shortage, leaving unmet the need for off-the-shelf 
available regenerative heart valve replacements. Clinical translation 
of the easily accessible xenogeneic valves, based on decellularized 
porcine tissues, has contradictory results, with reported sudden 
structural failure, severe stenosis, and need for re-operation in 
above 50% of the patients [64–66]. The causes of these failures re-
side in the residual immunogenicity of the decellularized xenoge-
neic tissue that determines a severe inflammatory response [64, 
67]. These dramatic results underline the preference for allogeneic 
material for clinical application and exemplify the need for novel 
alternative valves.
As the applicability of autologous in vitro cultured TEHVs is 
limited by the donor-to-donor variability and logistical hurdles, 
the use of an off-the-shelf available decellularized engineered valve 
may provide a solution. The less mature, in vitro grown ECM of 
the decellularized tissue-engineered matrices is hypothesized to 
allow for enhanced cell infiltration, leading to better repopulation 
capacity upon in vivo implantation [44]. However, the complete 
decellularization of the tissue is crucial as residual cells and cell 
remnants might lead to a strong inflammatory response and valve 
calcification [68]. 
Scaffold geometry and material porosity determine the level of 
cell infiltration and can be controlled using different methods of 
scaffold fabrication (e.g., electrospinning, mold casting, particulate 
leaching, and 3D-printing) [69]. Additionally, by immobilizing 
specific biomolecules (e.g., proteins, peptides, and antibodies), im-
proved biocompatibility as well as cell recruitment and differentia-
tion can be obtained [15]. As an example, the controlled release of 
inflammatory cytokines and chemokines (e.g., IL-8 and monocyte 
chemotactic protein-1), which are potent cell attractants and acti-
vators, was hypothesized to determine the fate of the implanted 
scaffold towards either a successful integration or a pathological 
chronic outcome [53]. 
In order to profit from the full potential of scaffold materials for 
in situ tissue engineering, multidisciplinary in-depth knowledge on 
the material properties, scaffold design, and scaffold functionaliza-
tion is required. 
Clinical Challenges: Beating the Gold Standard Valve 
Replacements
To encourage the adaptation of the TEHVs in routine clinical 
practice the off-the-shelf availability and the sterility of the product 
Table 2. Overview of clinical studies investigating the potentiality of in vitro TEHVs using decellularized pulmonary allografts and xenografts as starting  scaffold 
material
Cells Culture Patient cohort Main results Year
Allografts
Autologous vascular ECs 4 weeks in bioreactor 1 adult patient 1 year follow-up
excellent functionality
2002
[58]
Autologous blood progenitor  
cells 
3 weeks in bioreactor 2 pediatric patients 3 years follow-up
safe and feasible procedure
good functionality, even if mild to moderate regurgitation
2006
[60]
Autologous vascular ECs 4 weeks in bioreactor 11 patients 10 year follow-up
excellent hemodynamics
no signs of degeneration or calcification
2011
[59]
Xenografts 
Autologous vascular ECs 4 weeks in bioreactor 12 patients 5 years follow-up
good functionality
no signs of degeneration
2007
[18]
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as well as the ease of handling of the device and suitability for the 
different implantation techniques are highly relevant. Minimally 
invasive transcathether implantation techniques have had a rapid 
evolution in the past 10 years, reducing the risks and costs associ-
ated with the intervention. Being limited only to the use of bio-
prostheses, the transcathether techniques can be potentially com-
bined with the different types of TEHVs, as demonstrated in sheep 
[33, 44, 70], goats [56], and baboons [45]. In addition, the feasibil-
ity of combining TEHVs with a clinically used stent and delivery 
device was also recently shown [71]. Still, to enable the full regen-
erative potential of transcathether valves, this approach should be 
complemented by innovative stent designs that allow for controlled 
dilatation or reabsorption upon implantation [72]. 
In addition, the different regenerative potential among patients 
is of great concern, because cell infiltration, adhesion, and ECM 
production may be age-dependent and influenced by comorbidi-
ties. To predict the clinical outcome from the results of pre-clinical 
experiments, a clear correlation between animal and human data 
has to be identified. The development of specific in vitro model 
systems would be beneficial to study the inter-patient and inter-
species variability in the response to the implanted materials. Fur-
ther, the phenotype of the macrophages recruited into the im-
planted scaffold can potentially forecast the direction of the in vivo 
remodeling response to either chronic inflammation or healing 
[73]. 
Clinical success of the TEHV replacements depends on logistics 
considerations: off-the-shelf availability, ease of storage, and trans-
portation. For replacements based on living cells, the only method 
to increase the product lifetime is by cryopreservation. To limit 
damage to the tissue caused by the freezing process [74], research-
ers have introduced the use of different methods (e.g., cryoprotec-
tive media [75] and vitrification [76]) to control the ice crystal for-
mation. Similarly, lyophilization can improve the shelf life of decel-
lularized tissues or engineered matrix. To retain the structural in-
Table 3. Overview of clinical studies investigating the potentiality of in-situ TEHVs based on decellularized allografts and xenografts as scaffold material
Type of valve Surgical procedure Patient cohort Main results Year
Allografts
Decellularized pulmonary  
valve
Ross procedure 15 patients 6 months follow-up
promising hemodynamics and functionality
good morphology
2003
[86]
Decellularized pulmonary  
valve
Ross procedure 11 patients 18 months follow-up
reduction of the immunogenic response
promising functionality
2005
[87]
Decellularized aortic valve aortic root replacement 22 patients 1 year follow-up
good functionality
low to none immunoreactivity
2005
[88]
Decellularized aortic valve aortic root replacement 41 patients 4 years follow-up
adequate hemodynamics
structural integrity over time
no calcification
2010
[89]
Decellularized pulmonary  
valve
Ross procedure 29 patients 5 years follow-up
promising functionality and hemodynamic profile
2011
[90]
Decellularized pulmonary  
valve
pulmonary valve  
replacement
38 patients 5 years follow-up
100% freedom from re-operation
adaptive growth in pediatric patients 
2011
[62]
Decellularized pulmonary  
valve
pulmonary valve  
replacement
93 patients 10 years follow-up
100% freedom from re-operation
good functionality and hemodynamic profile
2016
[63]
Xenografts
Decellularized porcine  
valve
Ross procedure 50 patients 2 years follow-up
physiological-like behavior
36% needed a re-operation
2005
[91]
Decellularized porcine  
valve
pulmonary valve  
replacement
16 young patients stenosis
severe thickening of the intima
2010
[66]
Decellularized porcine  
valve
right ventricle outflow  
tract
61 patients  
(18 in infancy)
3 years follow-up
100% freedom of re-operation for pediatric patients
favorable performance and functionality
2011
[92]
Decellularized porcine  
valve
pulmonary valve  
replacement
26 young patients average life span of 19 months
14 failures that required re-operation
stenosis and insufficiency of the valve
foreign body response and inflammation
no endothelial cell coverage
2013
[65]
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tegrity and the final geometry of the product, the use of sucrose 
solution and/or the optimization of the freezing cycle temperatures 
may be necessary [77]. Finally, biodegradable polymer-based 
TEHVs for in situ applications do not require special processing, 
gaining further interest in the community. 
Optimization of the processes required to ensure product steril-
ity, availability, ease of handling, storage, and transportation will 
lead to the clinical success of the TEHV replacements.
Regulatory Challenges: Towards Commercialization 
The growing market for heart valve prostheses, valued at USD 
2.87 billion in 2014 and estimated to grow to USD 4.80 billion by 
2020 [2], attracts the attention of many biomedical companies. 
However, the novel TEHVs are difficult to assign in the classical 
Food and Drug Administration (FDA) classification. In fact, de-
vices containing living cells that have a clear pharmacological, im-
munological, or metabolic effect on the human body are usually 
classified as biological or pharmaceutical products. At the same 
time, decellularized materials or tissue-engineered constructs, 
where the matrix is the major mechanism of action and the func-
tion occurs by physical means (e.g., heart valves, blood vessels), can 
be either classified as medical or biological devices. Therefore, 
there is still the need for the FDA and other regulatory agencies 
worldwide to formulate regulations and documents to clarify these 
issues [78].
Before moving from bench to bedside, the production and test-
ing of the TEHVs should be performed in accordance to technical 
norms (e.g., ISO 13485 Medical Devices – Quality Management 
System – Requirements for Regulatory Purposes [79]; ISO 10993 
Biological Evaluation of Medical Devices [80]; ISO 5840 Cardio-
vascular Implants – Cardiac Valve Prosthesis [81]) and the product 
should be evaluated by an accredited notified body. To be able to 
accommodate for the different technical guidelines and require-
ments of Europe, Japan and the USA, the production, pre-clinical 
and clinical evaluation of the product should be performed in ac-
cordance to the International Council on Harmonisation of Tech-
nical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH). The ICH guidelines aim at ensuring safety (e.g., to un-
cover potential risks like carcinogenicity or genotoxicity), quality 
(e.g., stability studies, definition of thresholds for impurities, and 
good manufacturing practice compliance), and efficacy (e.g., re-
lated to the design, conduct, safet,y and reporting of clinical trials) 
of the product.
The process of harmonization would lead to the production of a 
product ready for commercialization in the different areas, while 
ensuring quality, safety, efficacy, and regulatory obligations to pro-
tect public health.
Conclusions 
Lifetime expectancy is constantly increasing, leading to more 
and more patients in need of a valve replacement with prolonged 
durability. In order to solve this problem, several tissue engineer-
ing approaches have been developed over the last years, showing 
promising in vitro, pre-clinical, and even clinical results. Engi-
neered valve replacements with regenerative capacity have the po-
tential to offer a lifelong solution for the increasing numbers of 
cardiovascular patients worldwide. However, their translation into 
clinics depends on their superiority compared to today’s biopros-
thetic valves. Despite the enormous progress in the development of 
TEHVs that have showed regenerative potential in pre-clinical 
studies, a clinically relevant product is not yet realized. Therefore, 
research in the field of cardiovascular tissue engineering should 
focus on the understanding of the structural and biological proper-
ties of the native valves that ensure its efficiency and functionality. 
The most recently introduced in situ approaches that enable off-
the-shelf availability and exploit the regenerative capacity of the 
body to remodel and form new tissue upon orthotopic implanta-
tion were reviewed here. These prostheses hold large promises for 
clinical translation, as they represent a less complex and substan-
tially less costly alternative to replacements obtained via the classic 
in vitro tissue engineering paradigm. By improving scaffold fabri-
cation strategies, it will become possible to replicate the physiologi-
cal complexity and instruct cell differentiation and remodeling of 
seeded or endogenously recruited cells. Despite the necessary fu-
ture developments, preclinical results demonstrated that engi-
neered artificial valves do bare regenerative capacity and promise 
to improve the quality of life of younger and older patients alike.
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